Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
Last trade$0.5957
Day change-$0.0658 (-9.95%)
Day range$0.571 – $0.696
Volume2,135,918
Market cap$119M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$118.86M
Price / earnings
—
Price / book
0.83×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.82×
Profitability
Earnings per share
-$0.48
Return on assets
-49.49%
Return on equity
-60.57%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
6.79×
Quick ratio
6.79×
Cash ratio
1.7×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$61.94M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CMPX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$6.76M
$7.4M
$6.91M
$4.32M
$2.99M
$4.65M
$4.91M
$3.54M
Research and development
$22.04M
$19.58M
$13.39M
$13.67M
$12.83M
$16.42M
$13.05M
$13.04M
Total operating expenses
$28.8M
$26.98M
$20.3M
$17.99M
$15.82M
$21.07M
$17.97M
$16.57M
Operating income
-$28.8M
-$26.98M
-$20.3M
-$17.99M
-$15.82M
-$21.07M
-$17.97M
-$16.57M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$27.17M
-$25.15M
-$18.32M
-$15.72M
-$14.26M
-$19.88M
-$16.63M
-$15.03M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$27.17M
-$25.15M
-$18.32M
-$15.72M
-$14.26M
-$19.88M
-$16.63M
-$15.03M
Net income attributable to common shareholders
-$27.17M
-$25.15M
-$18.32M
-$15.72M
-$14.26M
-$19.88M
-$16.63M
-$15.03M
EBITDA
-$28.77M
-$26.96M
-$20.28M
-$17.97M
-$15.8M
-$20.97M
-$17.83M
-$16.43M
Basic earnings per share
-$0.15
-$0.13
-$0.10
-$0.08
-$0.08
-$0.14
-$0.12
-$0.11
Diluted earnings per share
-$0.15
-$0.13
-$0.10
-$0.08
-$0.08
-$0.14
-$0.12
-$0.11
Recent news
Company coverage with links to the original publishers.
Compass Therapeutics announced positive Phase 2/3 COMPANION-002 results for tovecimig in combination with paclitaxel for previously treated advanced biliary tract cancer, meeting primary endpoint of ORR (18.0% vs 5.3%) and key secondary endpoint of PFS with 56% reduction in disease progression risk. However, the intent-to-treat OS analysis showed no statistically significant difference due to high crossover rates (85% of patients ultimately received tovecimig). Safety profile was consistent with prior studies and the anti-VEGF class.
Compass Therapeutics announced that its abstract for tovecimig, a DLL4 x VEGF-A bispecific antibody, has been accepted for an oral presentation at the ESMO Congress 2026 in Madrid. The presentation will showcase Phase 2/3 COMPANION-002 trial results evaluating tovecimig combined with paclitaxel in patients with advanced biliary tract cancer, to be presented by Dr. Nilofer Azad from Johns Hopkins University on October 24, 2026.
Compass Therapeutics announced Phase 1 clinical data for CTX-8371, a novel PD-1×PD-L1 bispecific antibody, showing promising monotherapy activity in patients with advanced malignancies resistant to prior checkpoint inhibitors. The drug demonstrated deep and durable responses in triple-negative breast cancer, Hodgkin lymphoma, and non-small cell lung cancer, with a 33% overall response rate at the highest dose levels and no dose-limiting toxicities observed.
Johnson Fistel, PLLP is investigating potential securities law violations by Compass Therapeutics following the disclosure that its lead drug candidate tovecimig failed to meet the overall survival secondary endpoint in the COMPANION-002 clinical trial. The company reported median overall survival of 8.9 months versus 9.4 months for the control arm, resulting in significant stock price decline. Investors who suffered losses are encouraged to contact the firm.
Compass Therapeutics will host a webcast on April 27, 2026 to present topline secondary endpoints from its Phase 2/3 COMPANION-002 study evaluating tovecimig, a DLL4 x VEGF-A bispecific antibody combined with paclitaxel, in patients with advanced biliary tract cancer. The study has reached its prespecified event threshold of 80% overall survival events.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.